Pioglitazone modulates the balance of effector and regulatory T cells in apolipoprotein E deficient mice

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 1, 2011, Pages 25-32

  Tian, Y ^a   Yuan, Z ^a   Liu, Y ^a   Liu, W ^a   Zhang, W ^a   Xue, J ^a   Shen, Y ^a   Liang, X ^a   Chen, T ^a   Kishimoto, C ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Foxp3; Pioglitazone; PPAR ; T cells

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; APOLIPOPROTEIN E; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; GAMMA INTERFERON; INTERLEUKIN 4; LIPID; PIOGLITAZONE; RNA;

ANIMAL; ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD; DISEASE COURSE; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; TH1 CELL; TH2 CELL;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CYTOKINES; DISEASE PROGRESSION; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; INTERLEUKIN-4; LIPID METABOLISM; LIPIDS; MICE; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SPLEEN; TH1 CELLS; TH2 CELLS; THIAZOLIDINEDIONES;

MUS;

EID: 78751615823     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.07.010     Document Type: Article

References (25)

1. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001, 7:48-52.
2. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., Padula S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000, 16:1364-1371.
3. Laclaustra M., Corella D., Ordovas J.M. Metabolic syndrome pathophysiology: the role of adipose tissue. Nutr Metab Cardiovasc Dis 2007, 17:125-139.
4. Kota B.P., Huang T.H., Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharm Res 2005, 51:85-94.
5. Chen Z., Ishibashi S., Perrey S., Osuga Ji., Gotoda T., Kitamine T., et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001, 21:372-377.
6. Collins A.R., Meehan W.P., Kintscher U., Jackson S., Wakino S., Noh G., et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:365-371.
7. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
8. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 2007, 298:1180-1188.
9. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
10. Thorp E., Kuriakose G., Shah Y.M., Gonzalez F.J., Tabas I. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Circulation 2007, 116:2182-2190.
11. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
12. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9:239-244.
13. Ait-Oufella H., Salomon B.L., Potteaux S., Robertson A.K., Gourdy P., Zoll J., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12:178-180.
14. Gotsman I., Grabie N., Gupta R., Dacosta R., MacConmara M., Lederer J., et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006, 114:2047-2055.
15. Mor A., Planer D., Luboshits G., Afek A., Metzger S., Chajek-Shaul T., et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:893-900.
16. Yuan Z., Liu Y., Liu Y., Zhang J., Kishimoto C., Wang Y., et al. Peroxisome proliferation-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis. Cardiovasc Res 2003, 59:685-694.
17. Wohlfert E.A., Nichols F.C., Nevius E., Clark R.B. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol 2007, 178:4129-4135.
18. Yuan Z., Kishimoto C., Sano H., Shioji K., Xu Y., Yokode M. Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol Heart Circ Physiol 2003, 285:H899-H906.
19. Game B.A., He L., Jarido V., Nareika A., Jaffa A.A., Lopes-Virella M.F., et al. Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice. Atherosclerosis 2007, 192:85-91.
20. Hennuyer N., Tailleux A., Torpier G., Mezdour H., Fruchart J.C., Staels B., et al. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 2005, 25:1897-1902.
21. Pinderski L.J., Fischbein M.P., Subbanagounder G., Fishbein M.C., Kubo N., Cheroutre H., et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002, 90:1064-1071.
22. van Puijvelde G.H., van Es T., van Wanrooij E.J., Habets K.L., de Vos P., van der Zee R., et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:2677-2683.
23. Alyanakian M.A., You S., Damotte D., Gouarin C., Esling A., Garcia C., et al. Diversity of regulatory CD4+ T cells controlling distinct organ-specific autoimmune diseases. Proc Natl Acad Sci USA 2003, 100:15806-15811.
24. Laurat E., Poirier B., Tupin E., Caligiuri G., Hansson G.K., Bariéty J., et al. In vivo downregulation of T helper cell 1 immune responses reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001, 104:197-202.
25. Gupta S., Pablo A.M., Jiang X., Wang N., Tall A.R., Schindler C. IFN-g potentiates atherosclerosis in apoE knock-out mice. J Clin Invest 1997, 99:2752-2761.